{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:49:58Z","timestamp":1792093798330,"version":"4.4.0"},"reference-count":46,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PMP15\/00027"],"award-info":[{"award-number":["PMP15\/00027"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union-ERDF","award":["PMP22\/00021"],"award-info":[{"award-number":["PMP22\/00021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective trial (21 university hospitals) comparing the effectiveness and time-to-control of 2 treatment protocols during 12 months: (A) a personalized protocol in which the first options were fgSRLs as monotherapy or in combination with pegvisomant, or pegvisomant as monotherapy depending on the short acute octreotide test (sAOT) results, tumor T2 magnetic resonance (MRI) signal or immunostaining for E-cadherin; and (B) a control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, P &amp;lt; .05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2.53 (CI, 1.30-4.80). Patients from the personalized arm were controlled in a shorter period of time (P = .01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Personalized medicine is feasible using a relatively simple protocol, and it allows a higher number of patients to achieve control in a shorter period of time.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae444","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:31:27Z","timestamp":1719534687000},"page":"30-40","source":"Crossref","is-referenced-by-count":30,"title":["Personalized Medicine in Acromegaly: The ACROFAST Study"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-5070","authenticated-orcid":false,"given":"Montserrat","family":"Marques-Pamies","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Municipal de Badalona , Badalona 08911 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1030-9119","authenticated-orcid":false,"given":"Joan","family":"Gil","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP) , Badalona 08916 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), Instituto de Salud Carlos III (ISCIII) , Barcelona 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sampedro-Nu\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, La Princesa University Hospital , Madrid 28006 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Valassi","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP) , Badalona 08916 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), Instituto de Salud Carlos III (ISCIII) , Barcelona 28029 ,","place":["Spain"]},{"name":"Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8837-4343","authenticated-orcid":false,"given":"Betina","family":"Biagetti","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Vall Hebron University Hospital , Barcelona 08035 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Gim\u00e9nez-Palop","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Parc Taul\u00ed University Hospital , Sabadell 08208 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Arnau de Vilanova University Hospital , Lleida 25198 ,","place":["Spain"]},{"name":"Endocrine Research Unit, Lleida Institute for Biomedical Research Dr. Pifarr\u00e9 Foundation (IRBLleida) , Lleida 25198 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Department Hormonal Laboratory, Germans Trias i Pujol University Hospital , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Carrato","sequence":"additional","affiliation":[{"name":"Department of Pathology, Germans Trias i Pujol University Hospital , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Villar-Taibo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cl\u00ednico de Santiago University Hospital , Santiago de Compostela 15706 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Ram\u00f3n y Cajal University Hospital , Madrid 28034 ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Ram\u00f3n y Cajal (IRYCIS) , Madrid 28034 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Blanco","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Pr\u00edncipe de Asturias University Hospital , Madrid 28805 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Sim\u00f3n-Muela","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Joan XXIII University Hospital , Tarragona 43005 ,","place":["Spain"]},{"name":"Endocrine Research Unit, Institut d\u00b4Investigaci\u00f3 Sanit\u00e0ria Pere Virgili (IISPV) , Tarragona 43005 ,","place":["Spain"]},{"name":"Rovira i Virgili University (URV) , Tarragona 43003 ,","place":["Spain"]},{"name":"Endocrine Research Unit, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) , Hospitalet de LLobregat 08907 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Sim\u00f3-Servat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Mutua de Terrassa University Hospital , Terrassa 08221 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Xifra","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Josep Trueta University Hospital , Girona 17007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Pav\u00f3n","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Getafe University Hospital , Madrid 28905 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Rosado","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Getafe University Hospital , Madrid 28905 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Garc\u00eda-Centeno","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Gregorio Mara\u00f1\u00f3n University Hospital , Madrid 28007 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Zavala","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Joan XXIII University Hospital , Tarragona 43005 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia Alexandra","family":"Hanzu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Clinic University Hospital , Barcelona 08036 ,","place":["Spain"]},{"name":"Endocrine Research Unit, Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS) , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Mora","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Clinic University Hospital , Barcelona 08036 ,","place":["Spain"]},{"name":"Endocrine Research Unit, Institut d\u2019Investigacions Biom\u00e8diques August Pi I Sunyer (IDIBAPS) , Barcelona 08036 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Aulinas","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), Instituto de Salud Carlos III (ISCIII) , Barcelona 28029 ,","place":["Spain"]},{"name":"Department of Endocrinology and Nutrition, Research Center for Pituitary Diseases, Institut de Recerca Sant Pau (IIB-Sant Pau), Hospital Sant Pau , Barcelona 08041 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Vilarrasa","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) , Hospitalet de LLobregat 08907 ,","place":["Spain"]},{"name":"Department of Endocrinology and Nutrition, Bellvitge University Hospital , Hospitalet de Llobregat 08907 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Diabetes y Enfermedades Metab\u00f3licas (CIBERDEM), Instituto de Salud Carlos III (ISCIII) , Madrid 28029 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soledad","family":"Librizzi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, 12 de Octubre University Hospital , Madrid 28041 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Calatayud","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, 12 de Octubre University Hospital , Madrid 28041 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"de Miguel","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cl\u00ednico San Carlos University Hospital , Madrid 2546 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Alvarez-Escola","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, La Paz University Hospital , Madrid 28046 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pic\u00f3","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, General University Hospital Dr Balmis, Miguel Hern\u00e1ndez University , Alicante 03010 ,","place":["Spain"]},{"name":"Endocrine Research Unit, Instituto de Investigaci\u00f3n Sanitaria y Biom\u00e9dica de Alicante (ISABIAL) , Alicante 03010 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Salinas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Fajardo-Monta\u00f1ana","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, La Ribera University Hospital , Valencia 46600 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"C\u00e1mara","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, La Fe University Hospital , Valencia 46026 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Bernab\u00e9u","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Cl\u00ednico de Santiago University Hospital , Santiago de Compostela 15706 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireia","family":"Jord\u00e0","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP) , Badalona 08916 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Webb","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), Instituto de Salud Carlos III (ISCIII) , Barcelona 28029 ,","place":["Spain"]},{"name":"Department of Endocrinology and Nutrition, Research Center for Pituitary Diseases, Institut de Recerca Sant Pau (IIB-Sant Pau), Hospital Sant Pau , Barcelona 08041 ,","place":["Spain"]},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona (UAB) , Bellaterra 08193 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Marazuela","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, La Princesa University Hospital , Madrid 28006 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-7195","authenticated-orcid":false,"given":"Manel","family":"Puig-Domingo","sequence":"additional","affiliation":[{"name":"Endocrine Research Unit, Germans Trias i Pujol Research Institute (IGTP) , Badalona 08916 ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER, Unidad 747), Instituto de Salud Carlos III (ISCIII) , Barcelona 28029 ,","place":["Spain"]},{"name":"Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital , Badalona 08916 ,","place":["Spain"]},{"name":"Departament de Medicina, Universitat Aut\u00f2noma de Barcelona (UAB) , Bellaterra 08193 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,6,29]]},"reference":[{"issue":"9","key":"2024121723533719900_dgae444-B1","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2024121723533719900_dgae444-B2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"2024121723533719900_dgae444-B3","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024121723533719900_dgae444-B4","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024121723533719900_dgae444-B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11102-019-01020-3","article-title":"Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study","volume":"23","author":"Petersenn","year":"2020","journal-title":"Pituitary"},{"issue":"8","key":"2024121723533719900_dgae444-B6","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2005-0260","article-title":"Long-acting somatostatin analog therapy of acromegaly: a meta-analysis","volume":"90","author":"Freda","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024121723533719900_dgae444-B7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"8","key":"2024121723533719900_dgae444-B8","doi-asserted-by":"crossref","first-page":"102924","DOI":"10.1016\/j.arcmed.2023.102924","article-title":"Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly","volume":"54","author":"Marques-Pamies","year":"2023","journal-title":"Arch Med Res"},{"key":"2024121723533719900_dgae444-B9","doi-asserted-by":"crossref","first-page":"1269787","DOI":"10.3389\/fendo.2023.1269787","article-title":"Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly","volume":"14","author":"Marques-Pamies","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2024121723533719900_dgae444-B10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1507\/endocrj.EJ16-0175","article-title":"The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly","volume":"63","author":"Wang","year":"2016","journal-title":"Endocr J"},{"issue":"6","key":"2024121723533719900_dgae444-B11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-2008-1065339","article-title":"A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients","volume":"40","author":"Halperin","year":"2008","journal-title":"Horm Metab Res"},{"issue":"11","key":"2024121723533719900_dgae444-B12","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024121723533719900_dgae444-B13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2024121723533719900_dgae444-B14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024121723533719900_dgae444-B15","doi-asserted-by":"crossref","first-page":"101502","DOI":"10.1016\/j.ghir.2022.101502","article-title":"Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study","volume":"67","author":"Durmu\u015f","year":"2022","journal-title":"Growth Horm IGF Res"},{"issue":"11","key":"2024121723533719900_dgae444-B16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00234-016-1728-4","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","journal-title":"Neuroradiology"},{"issue":"2","key":"2024121723533719900_dgae444-B17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"issue":"1","key":"2024121723533719900_dgae444-B18","first-page":"12","article-title":"Resistance to somatostatin analogs in Italian Acromegaly patients: The MISS study","volume":"12","author":"Berton","year":"2023","journal-title":"J Clin Med"},{"issue":"3","key":"2024121723533719900_dgae444-B19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024121723533719900_dgae444-B20","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2024121723533719900_dgae444-B21","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly\u2014a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024121723533719900_dgae444-B22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"key":"2024121723533719900_dgae444-B23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2015.09.016","article-title":"Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumors","volume":"417","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"2024121723533719900_dgae444-B24","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1210\/jc.2009-2197","article-title":"The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response","volume":"95","author":"Fougner","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024121723533719900_dgae444-B25","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2024121723533719900_dgae444-B26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2024121723533719900_dgae444-B27","doi-asserted-by":"crossref","first-page":"648411","DOI":"10.3389\/fendo.2021.648411","article-title":"Pasireotide in the personalized treatment of Acromegaly","volume":"12","author":"Puig-Domingo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2024121723533719900_dgae444-B28","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"2024121723533719900_dgae444-B29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2024121723533719900_dgae444-B30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1530\/EJE-18-0015","article-title":"Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study","volume":"178","author":"Esposito","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2024121723533719900_dgae444-B31","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"1","key":"2024121723533719900_dgae444-B32","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2024121723533719900_dgae444-B33","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12020-014-0521-6","article-title":"Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire","volume":"49","author":"Vandeva","year":"2015","journal-title":"Endocrine"},{"issue":"7","key":"2024121723533719900_dgae444-B34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1515\/CCLM.2011.201","article-title":"Harmonization of growth hormone measurements with different immunoassays by data adjustment","volume":"49","author":"M\u00fcller","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"2024121723533719900_dgae444-B35","first-page":"989","article-title":"The volume of the sella turcica","volume":"87","author":"Di Chiro","year":"1962","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"2024121723533719900_dgae444-B36","unstructured":"Marques-Pamies M, Gil J, Sampedro-Nu\u00f1ez M \u00a0et al \u00a0Data from Personalized medicine in acromegaly: The ACROFAST study. Figshare Repository 2024. Deposited 16 May 2024. 10.6084\/m9.figshare.25843276"},{"issue":"7","key":"2024121723533719900_dgae444-B37","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3390\/jcm10071363","article-title":"Towards an earlier diagnosis of acromegaly and gigantism","volume":"10","author":"Sisco","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"2024121723533719900_dgae444-B38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cen.12731","article-title":"Treatment of acromegaly in the era of personalized and predictive medicine","volume":"83","author":"Puig Domingo","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2024121723533719900_dgae444-B39","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of endocrine disease: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024121723533719900_dgae444-B40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1530\/EJE-21-0239","article-title":"More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY","volume":"185","author":"Fleseriu","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2024121723533719900_dgae444-B41","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024121723533719900_dgae444-B42","doi-asserted-by":"crossref","first-page":"984877","DOI":"10.3389\/fendo.2022.984877","article-title":"Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain","volume":"13","author":"Biagetti","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2024121723533719900_dgae444-B43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2024121723533719900_dgae444-B44","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2024121723533719900_dgae444-B45","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/cen.14946","article-title":"Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly","volume":"99","author":"Ruiz","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2024121723533719900_dgae444-B46","doi-asserted-by":"crossref","first-page":"101684","DOI":"10.1016\/j.beem.2022.101684","article-title":"Second line treatment of acromegaly: Pasireotide or Pegvisomant?","volume":"36","author":"Chiloiro","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae444\/59556951\/dgae444.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/1\/30\/61213696\/dgae444.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/1\/30\/61213696\/dgae444.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T18:54:36Z","timestamp":1734461676000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/1\/30\/7701741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,6,29]]},"published-print":{"date-parts":[[2024,12,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae444","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,6,29]]}}}